|
Aeolus Pharmaceuticals is developing AEOL 10150, a small molecule
catalytic antioxidant that has shown the ability to scavenge a broad
range of reactive oxygen species. AEOL 10150 is currently undergoing
human clinical evaluation in patients with ALS. James Crapo, MD, and
Brian Day, PhD, of National Jewish Health are inventors on the
intellectual property underlying this discovery. |
| |
|
|
Juvaris BioTherapeutics was founded in 2003, based on the intellectual
property developed at National Jewish Health by Steven Dow, DVM, PhD.
Juvaris BioTherapeutics is developing therapeutic vaccines for cancer
and infectious diseases using its novel technology platform of cationic
lipids and non-coding DNA complexes. |
| |
|
|
Taiga Biotechnologies was founded to develop novel approaches to treat
hematological diseases, including cancers, immunodeficiencies and
autoimmune conditions. Their three-pronged approach combines novel
breakthroughs by Yosef Refaeli, PhD, John Cambier, PhD, and colleagues
at National Jewish Health and University of Colorado Denver in
cellular, biologic and small molecule approaches to treat and manage
these diseases. |
| |
|
|
Taligen Therapeutics, Inc., which was founded in March 2004 by Drs.
Woody Emlen and V. Michael Holers, is working to develop and
commercialize technologies created by scientists from National Jewish
Health (Erwin Gelfand, MD) and the University of Colorado Denver.
Taligen is a development stage biotechnology company focused on the
treatment of serious inflammatory diseases including asthma, macular
degeneration and immune kidney disease. The Company employs novel
technologies designed to modulate and regulate activation of the
complement system. |
| |
|
|
VistaGen applies their innovative in vitro embryonic stem (ES) cell
technologies to discover and develop new generation drugs and protein
biologics, both internally and through strategic collaborations with
the pharmaceutical and biotechnology industries. Vistagen's clinically
predictive in vitro embryonic stem cell technologies are based on
intellectual property developed at National Jewish Health by Gordon
Keller, PhD. |
